Cargando…

Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma

BACKGROUND: To investigate on the expressions and the clinical significances of hepatocyte growth factor receptor (c-MET), phosphorylated c-MET (p-MET) and e2f-1 transcription factor in primary lesion of gastric adenocarcinoma (GC). METHOD: Tissue samples from the primary lesion of GC in patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Ju-gang, Yu, Ji-wei, Wu, Hong-biao, Zheng, Lin-hai, Ni, Xiao-chun, Li, Xiao-qiang, Du, Guang-ye, Jiang, Bo-jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895664/ https://www.ncbi.nlm.nih.gov/pubmed/24393368 http://dx.doi.org/10.1186/1756-0500-7-6

Ejemplares similares

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer
por: Liao, Haiyan, et al.
Publicado: (2021)

Expression and Significances of Contactin-1 in Human Gastric Cancer
por: Yu, Ji-Wei, et al.
Publicado: (2013)

Influencing factors and clinical significance of the metastatic lymph nodes ratio in gastric adenocarcinoma
por: Yu, Ji-wei, et al.
Publicado: (2009)

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
por: Peng, Lun-Xi, et al.
Publicado: (2021)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
por: Park, Chi Hoon, et al.
Publicado: (2016)

Clinical Significance of MET Gene Copy Number in Patients with Curatively Resected Gastric Cancer
por: Kang, Byung Woog, et al.
Publicado: (2015)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC
por: Jie, Guang-Ling, et al.
Publicado: (2023)

Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts
por: Ji, Fujian, et al.
Publicado: (2015)

Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer
por: Lin, Xiaoting, et al.
Publicado: (2019)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

Expression of MACC1 and c-Met in human gastric cancer and its clinical significance
por: Guo, Tiankang, et al.
Publicado: (2013)

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
por: Jardim, Denis L. Fontes, et al.
Publicado: (2014)

Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer
por: Wu, Zheng, et al.
Publicado: (2015)

(18)F-fluorodeoxyglucose uptake predicts MET expression in lung adenocarcinoma
por: An, Shuxian, et al.
Publicado: (2017)

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
por: Kou, Jianqun, et al.
Publicado: (2018)

Critical Role of MetR/MetB/MetC/MetX in Cysteine and Methionine Metabolism, Fungal Development, and Virulence of Alternaria alternata
por: Gai, Yunpeng, et al.
Publicado: (2021)

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
por: Miyamoto, M, et al.
Publicado: (2011)

Preliminary Study on the Expression and the Clinical Significance of CD133 in Peripheral Blood of Patients with Gastric Adenocarcinoma
por: Wu, Ju-gang, et al.
Publicado: (2014)

Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis
por: Peng, Zhi, et al.
Publicado: (2014)

Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression
por: NOGUCHI, EIICHIRO, et al.
Publicado: (2015)

MET Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?
por: El Darsa, Haidar, et al.
Publicado: (2020)

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2021)

Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET-amplified patient-derived gastric cancer xenografts
por: LIU, KAI, et al.
Publicado: (2015)

Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma
por: Chun, Hyung-Wook, et al.
Publicado: (2019)

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer
por: Sun, Dantong, et al.
Publicado: (2023)

Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma
por: Yu, Ji-wei, et al.
Publicado: (2010)

Expression and Significance of CD44, CD47 and c-met in Ovarian Clear Cell Carcinoma
por: Wang, Huimin, et al.
Publicado: (2015)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Clinicopathological and prognostic significance of c-Met overexpression in breast cancer
por: Zhao, Xixi, et al.
Publicado: (2017)

Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis
por: Pyo, Jung-Soo, et al.
Publicado: (2016)

Role of HGF/c‐Met in the treatment of colorectal cancer with liver metastasis
por: Yao, Jian‐feng, et al.
Publicado: (2019)

Tackling CASMI 2012: Solutions from MetFrag and MetFusion
por: Ruttkies, Christoph, et al.
Publicado: (2013)

Everolimus induces Met inactivation by disrupting the FKBP12/Met complex
por: Raimondo, Lucia, et al.
Publicado: (2016)

Medemens als medicijn: Beter contact met iemand met dementie
por: Bormans, Kasper
Publicado: (2020)

c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer
por: Kang, Chung Hyo, et al.
Publicado: (2021)

PKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells
por: Wu, Yan, et al.
Publicado: (2016)

Induction of an EMT-like transformation and MET in vitro
por: Ding, Songming, et al.
Publicado: (2013)

Structural basis of the activation of c-MET receptor
por: Uchikawa, Emiko, et al.
Publicado: (2021)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_25luj1hl59qq8a15fdta80ffmp